Have Questions?

Global Headquarters

Tel: +44 (0)20 7377 0800
Fax: +44 (0)20 7349 5157

North America

Tel: 1-617-573-9450
Fax: 1-617-573-9542


Tel: +81 (0)80-1164-4754

Request a Demo

What our customers are saying

When I think of the future, I think of EvaluatePharma

Senior Director,
Global pharmaceutical company

EP Vantage Pharma & Biotech Half-Year Review 2015


EvaluatePharma World Preview 2015, Outlook to 2020

Download EP Vantage Pharma & Biotech Half-Year Review 2015

The first half of 2015 has continued to confound the naysayers of the pharma industry, with deal making, venture funding and share price indices all showing now signs of slowing down.

Pharma & Biotech Half-Year Review 2015 highlights:

  • The year started with one of the biggest venture rounds ever with the $450 million Moderna Therapeutics managed to secure from its investors in January.
  • VCs gifted $3.8 billion to companies at the half-year point signifying that 2015 could once again raise the bar in terms of funding totals.
  • On average, the 32 floats this year yielded only a three percent discount from the listed range, and increased in value by 23% since their IPOs.

Press Release

Download EP Vantage Pharma & Biotech Half-Year Review 2015